Loading
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (1 ops.)
Latest filing published 03 Jan 2024 for GERON CORP.
Insider track record
Disclosed buys
2
Disclosed sells
1
T+90 hit rate
0%
T+90 mean return
-41.4%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Susan Molineaux: trading record in brief
Susan Molineaux (chief executive) discloses dealings in 3 companies, chiefly Geron Corp, Calithera Biosciences, Inc. and Theravance Biopharma, Inc. The record holds 56 filings, for trades running from 30 September 2013 to 29 December 2023.
The open-market side counts 2 purchases for €249k alongside 1 sale for €79k. Taken together, the purchases exceed the sales by €170k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 34 share grants and 17 option exercises.
The newest entry dates from 3 January 2024: a share grant, in Geron Corp. The clock since the last published purchase (10 November 2021) now reads 1,809 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Susan Molineaux
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations8 total
6,220 shares0Common StockSEC:0001209191-24-000546:0
6,191 shares0Common StockSEC:0001062993-23-018726:0
4,088 shares0Common StockSEC:0001062993-23-014272:0
35,000 shares@ US$1.10100.0% of flowCommon StockSEC:0001062993-23-009883:0
6,048 shares0Common StockSEC:0001062993-23-008380:0
526 shares@ US$0.44610.1% of flowCommon StockSEC:0000899243-23-002610:0
100,000 shares@ €0.730299.7% of flowCommon StockSEC:0000899243-21-044154:0
Canonical exit: 8 Feb 2022 (T+90)
2,712 sharesCommon StockSEC:0000886744-16-000043:0
8 of 8 declarations
